ArticleScientific reports2026
Mycophenolic acid exerts dichotomous regulation of hepatic lipogenesis in a metabolic context-dependent manner.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
With the increasing global burden of fatty liver disease (FLD), liver transplantation (LT) recipients face heightened risks of steatosis recurrence in graft livers, necessitating urgent reappraisal of immunosuppressant-associated metabolic effects. The effects of mycophenolic acid (MPA), a commonly used immunosuppressant in LT, on hepatic lipid metabolism following LT remain unclear. This study employed a multifaceted approach encompassing cellular, animal, and molecular biology techniques to systematically evaluate the role of MPA in hepatic lipid metabolism. Our results demonstrated that MPA promoted lipid synthesis in healthy hepatic models by upregulating the expression of genes associated with lipogenesis, including SREBP-1c, FASN, and PPARγ, while paradoxically inhibiting lipid accumulation in steatotic hepatic models. Mechanistically, we identified inosine monophosphate dehydrogenase 2 (IMPDH2) as the molecular switch governing this dichotomy. Notably, significantly increased interaction between IMPDH2 and PPARγ was observed following MPA treatment. Our findings highlight the intricate role of MPA in hepatic lipid homeostasis and underscore the importance of further elucidating the effects of MPA across a spectrum of liver conditions to inform tailored treatment strategies following LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.